» Articles » PMID: 11182394

Contralateral Prophylactic Mastectomy Improves the Outcome of Selected Patients Undergoing Mastectomy for Breast Cancer

Overview
Journal Am J Surg
Specialty General Surgery
Date 2001 Feb 22
PMID 11182394
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Risk factors for contralateral breast cancer (CBC) may indicate a benefit for contralateral prophylactic mastectomy (CPM) at the time of unilateral mastectomy for breast cancer. The purpose of this study is to evaluate the efficacy of CPM in preventing CBC.

Methods: sixty-four patients undergoing CPM and a control group of 182 patients not undergoing CPM and matched for age, stage, surgery, chemotherapy, and hormonal therapy were retrospectively compared for CBC rate, disease-free survival, and overall survival.

Results: Thirty-six CBCs occurred in the control group. In the CPM group, 3 CBCs were found at the time of prophylactic mastectomy, but none occurred subsequently (P = 0.005). Disease-free survival at 15 years in the CPM group was 55% (95% confidence interval [CI] 38% to 69%) versus 28% (95% CI 19% to 36%) in the control group (P = 0.01). Overall survival at 15 years was 64% (95% CI 45% to 78%) CPM versus 48% (95% CI 39% to 58%) in controls (P = 0.26).

Conclusion: CPM prevented CBC and significantly prolonged disease-free survival. Future studies will need to address risk assessment and contralateral breast cancer prevention in patients treated for early breast cancer.

Citing Articles

Society of Surgical Oncology Breast Disease Site Working Group Statement on Contralateral Mastectomy: Indications, Outcomes, and Risks.

Singh P, Agnese D, Amin M, Barrio A, van den Bruele A, Burke E Ann Surg Oncol. 2024; 31(4):2212-2223.

PMID: 38261126 DOI: 10.1245/s10434-024-14893-x.


Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in : Overall Survival, Racial, and Ethnic Differences.

Makhnoon S, Gutierrez Barrera A, Bassett R, Afrough A, Bedrosian I, Arun B Breast J. 2023; 2022:1447545.

PMID: 36685664 PMC: 9825211. DOI: 10.1155/2022/1447545.


Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?.

Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby J Breast. 2022; 67:30-35.

PMID: 36577271 PMC: 9982265. DOI: 10.1016/j.breast.2022.12.001.


De-escalating axillary surgery in early-stage breast cancer.

Hersh E, King T Breast. 2021; 62 Suppl 1:S43-S49.

PMID: 34949533 PMC: 9097808. DOI: 10.1016/j.breast.2021.11.018.


Utilization, Timing, and Outcomes of BRCA Genetic Testing Among Women With Newly Diagnosed Breast Cancer From a National Commercially Insured Population: The ABOARD Study.

Armstrong J, Lynch K, Virgo K, Schwartz M, Friedman S, Dean M JCO Oncol Pract. 2021; 17(2):e226-e235.

PMID: 33567243 PMC: 8202055. DOI: 10.1200/OP.20.00571.